354 related articles for article (PubMed ID: 21913025)
1. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
Bograd AJ; Suzuki K; Vertes E; Colovos C; Morales EA; Sadelain M; Adusumilli PS
Cancer Immunol Immunother; 2011 Nov; 60(11):1509-27. PubMed ID: 21913025
[TBL] [Abstract][Full Text] [Related]
2. What's the place of immunotherapy in malignant mesothelioma treatments?
Grégoire M
Cell Adh Migr; 2010; 4(1):153-61. PubMed ID: 20179421
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
Wong RM; Ianculescu I; Sharma S; Gage DL; Olevsky OM; Kotova S; Kostic MN; Grundfest WS; Hou D; Cameron RB
Am J Respir Cell Mol Biol; 2014 May; 50(5):870-5. PubMed ID: 24450537
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy and malignant mesothelioma: clinical perspectives].
Grégoire M; Ebstein F
Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.
Ceresoli GL; Bonomi M; Sauta MG
Expert Rev Anticancer Ther; 2016 Jul; 16(7):673-5. PubMed ID: 27224058
[No Abstract] [Full Text] [Related]
6. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
7. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
Lievense LA; Bezemer K; Cornelissen R; Kaijen-Lambers ME; Hegmans JP; Aerts JG
Lung Cancer; 2017 May; 107():36-40. PubMed ID: 27168021
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
9. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for immunotherapy in malignant pleural mesothelioma?
Tartarone A; Lerose R; Aieta M
Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
[TBL] [Abstract][Full Text] [Related]
11. Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?
Lucchi M; Picchi A; Alí G; Chella A; Guglielmi G; Cristaudo A; Fontanini G; Mussi A
Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):572-6. PubMed ID: 20053697
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
Tolani B; Acevedo LA; Hoang NT; He B
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
[TBL] [Abstract][Full Text] [Related]
13. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
Petrausch U; Schuberth PC; Hagedorn C; Soltermann A; Tomaszek S; Stahel R; Weder W; Renner C
BMC Cancer; 2012 Dec; 12():615. PubMed ID: 23259649
[TBL] [Abstract][Full Text] [Related]
14. A catalogue of treatment and technologies for malignant pleural mesothelioma.
Schunselaar LM; Quispel-Janssen JM; Neefjes JJ; Baas P
Expert Rev Anticancer Ther; 2016; 16(4):455-63. PubMed ID: 26943000
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
[TBL] [Abstract][Full Text] [Related]
16. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z
Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.
Lee HS; Jang HJ; Choi JM; Zhang J; de Rosen VL; Wheeler TM; Lee JS; Tu T; Jindra PT; Kerman RH; Jung SY; Kheradmand F; Sugarbaker DJ; Burt BM
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618661
[TBL] [Abstract][Full Text] [Related]
19. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
Katzman D; Sterman DH
Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
Minnema-Luiting J; Vroman H; Aerts J; Cornelissen R
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29601534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
